Ftse Mib
35.372,84
-0,11%
DAX
18.690,88
-0,19%
S&P 500
5.297,10
0,00%
NASDAQ
16.698,32
0,00%
Bitcoin
66.228,01
1,52%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD) Notizie

GILD

Gilead Sciences (GILD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GILD
DataOraFonteTitoloSimboloCompagnia
14/05/202416:09Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
09/05/202423:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
09/05/202422:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
09/05/202422:05Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramNASDAQ:GILDGilead Sciences Inc
08/05/202422:58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GILDGilead Sciences Inc
07/05/202414:30Business WireGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024NASDAQ:GILDGilead Sciences Inc
30/04/202422:05Business WireGilead Sciences to Present at Upcoming Investor ConferencesNASDAQ:GILDGilead Sciences Inc
26/04/202414:00Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIVNASDAQ:GILDGilead Sciences Inc
26/04/202413:47IH Market NewsExxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in EarningsNASDAQ:GILDGilead Sciences Inc
25/04/202422:02Business WireGilead Sciences Announces First Quarter 2024 Financial ResultsNASDAQ:GILDGilead Sciences Inc
25/04/202413:53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:GILDGilead Sciences Inc
08/04/202422:05Business WireGilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:GILDGilead Sciences Inc
28/03/202413:30Business WireFDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixNASDAQ:GILDGilead Sciences Inc
28/03/202412:00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
22/03/202414:18Business WireGilead Sciences Announces Completion of Acquisition of CymaBayNASDAQ:GILDGilead Sciences Inc
19/03/202400:29Business WireCenter for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink GrantNASDAQ:GILDGilead Sciences Inc
11/03/202413:34Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:GILDGilead Sciences Inc
11/03/202413:24Business WireGilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender OfferNASDAQ:GILDGilead Sciences Inc
06/03/202422:30Business WireBiktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and ComorbiditiesNASDAQ:GILDGilead Sciences Inc
06/03/202416:25Business WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NASDAQ:GILDGilead Sciences Inc
06/03/202414:00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:GILDGilead Sciences Inc
05/03/202422:35Business WireNew Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19NASDAQ:GILDGilead Sciences Inc
05/03/202422:30Business WireGilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public HealthNASDAQ:GILDGilead Sciences Inc
29/02/202422:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GILDGilead Sciences Inc
27/02/202416:00Business WireGilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.NASDAQ:GILDGilead Sciences Inc
26/02/202422:05Business WireU.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing ResistanceNASDAQ:GILDGilead Sciences Inc
26/02/202414:30Business WireGilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024NASDAQ:GILDGilead Sciences Inc
23/02/202412:09Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:GILDGilead Sciences Inc
20/02/202422:31Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GILDGilead Sciences Inc
14/02/202423:08Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:GILDGilead Sciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GILD

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
CPR
Davide Campari
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TITR
Telecom Italia
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network